<DOC>
	<DOCNO>NCT00324298</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , bleomycin , etoposide , cisplatin , work different way stop growth tumor cell , either kill cell stop divide . Giving one drug ( combination chemotherapy ) may kill tumor cell . It yet know schedule bleomycin effective give together etoposide cisplatin treat metastatic germ cell cancer testicle . PURPOSE : This randomized phase III trial study two different schedule bleomycin compare well work give together etoposide cisplatin treat patient metastatic germ cell cancer testicle .</brief_summary>
	<brief_title>Bleomycin , Etoposide , Cisplatin Treating Patients With Metastatic Germ Cell Cancer Testicles</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine long-infusion schedule bleomycin less toxic lung short-infusion schedule bleomycin patient undergoing combination chemotherapy comprise bleomycin , etoposide , cisplatin good-prognosis , metastatic germ cell cancer testes . - Determine early lung function test predictor late toxicity . - Determine indication enhance response long-infusion schedule justifies large-scale phase III evaluation . - Validate O'Sullivan et al prognostic score system bleomycin toxicity . Secondary - Determine response treatment . - Determine progression-free survival overall survival patient treat regimen . OUTLINE : This randomize , multicenter study . Patients stratify accord age ( ≤ 30 year vs &gt; 30 year ) , current smoker smoke within past 1 year ( yes v ) , creatinine clearance ( ≤ 80 mL/min v &gt; 80 mL/min ) . Patients randomize 1 2 treatment arm . - Arm I ( short-infusion schedule bleomycin ) : Patients receive etoposide IV 2 hour day 1-3 , cisplatin IV 4 hour day 1 2 , bleomycin IV 30 minute day 2 , 8 , 15 . - Arm II ( long-infusion schedule bleomycin ) : Patients receive etoposide cisplatin arm I . Patients also receive bleomycin IV continuously 72 hour day 1-3 . In arm , treatment repeat every 3 week 3 course absence disease progression unacceptable toxicity . After completion study treatment , patient follow 4 week every 3 month 24 month . Peer Reviewed Funded Endorsed Cancer Research UK PROJECTED ACCRUAL : A total 210 patient accrue study .</detailed_description>
	<mesh_term>Neoplasms , Germ Cell Embryonal</mesh_term>
	<mesh_term>Testicular Neoplasms</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Bleomycin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis metastatic germ cell cancer testes Goodprognosis disease Eligible treatment bleomycin , etoposide , cisplatin PATIENT CHARACTERISTICS : Creatinine clearance ≥ 60 mL/min No prior concurrent malignancy except basal cell skin cancer No major systemic illness No impaired respiratory function , include follow : Shortness breath minimal exertion Hypoxia rest Carbon monoxide transfer , total lung capacity , FEV_1 &gt; 60 % predict PRIOR CONCURRENT THERAPY : No prior chemotherapy radiotherapy</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>January 2007</verification_date>
	<keyword>drug/agent toxicity tissue/organ</keyword>
	<keyword>stage III malignant testicular germ cell tumor</keyword>
</DOC>